Prevalence and correlates of helminth co-infection in Kenyan HIV-1 infected adults

PLoS Negl Trop Dis. 2010 Mar 30;4(3):e644. doi: 10.1371/journal.pntd.0000644.

Abstract

Background: Deworming HIV-1 infected individuals may delay HIV-1 disease progression. It is important to determine the prevalence and correlates of HIV-1/helminth co-infection in helminth-endemic areas.

Methods: HIV-1 infected individuals (CD4>250 cells/ul) were screened for helminth infection at ten sites in Kenya. Prevalence and correlates of helminth infection were determined. A subset of individuals with soil-transmitted helminth infection was re-evaluated 12 weeks following albendazole therapy.

Results: Of 1,541 HIV-1 seropositive individuals screened, 298 (19.3%) had detectable helminth infections. Among individuals with helminth infection, hookworm species were the most prevalent (56.3%), followed by Ascaris lumbricoides (17.1%), Trichuris trichiura (8.7%), Schistosoma mansoni (7.1%), and Strongyloides stercoralis (1.3%). Infection with multiple species occurred in 9.4% of infections. After CD4 count was controlled for, rural residence (RR 1.40, 95% CI: 1.08-1.81), having no education (RR 1.57, 95% CI: 1.07-2.30), and higher CD4 count (RR 1.36, 95% CI: 1.07-1.73) remained independently associated with risk of helminth infection. Twelve weeks following treatment with albendazole, 32% of helminth-infected individuals had detectable helminths on examination. Residence, education, and CD4 count were not associated with persistent helminth infection.

Conclusions: Among HIV-1 seropositive adults with CD4 counts above 250 cells/mm(3) in Kenya, traditional risk factors for helminth infection, including rural residence and lack of education, were associated with co-infection, while lower CD4 counts were not.

Trial registration: ClinicalTrials.gov NCT00130910.

Publication types

  • Randomized Controlled Trial
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Albendazole / therapeutic use
  • Animals
  • Anthelmintics / therapeutic use
  • Comorbidity
  • Female
  • HIV Infections / complications*
  • HIV Infections / epidemiology*
  • HIV Infections / virology
  • HIV-1 / isolation & purification
  • Helminthiasis / drug therapy
  • Helminthiasis / epidemiology*
  • Helminths / classification
  • Helminths / isolation & purification*
  • Humans
  • Kenya / epidemiology
  • Male
  • Middle Aged
  • Prevalence
  • Risk Factors
  • Young Adult

Substances

  • Anthelmintics
  • Albendazole

Associated data

  • ClinicalTrials.gov/NCT00130910